title: Prevention of myopia progression with 0.05% atropine solution.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy of 0.05% atropine solution for controlling myopia progression in school-aged children.
  
  
  RESULTS
  This retrospective, case-control study enrolled myopic school-aged children who had presented at Kaohsiung Chang Gung Memorial Hospital (Kaohsiung, Taiwan) from 2001 to 2004. A group of 57 children (30 boys, 27 girls; 6-12 years of age) with regular follow-up was divided into a subgroup of 21 children (12 boys, 9 girls) who received atropine eyedrops (0.05%) every evening, and a subgroup of 36 children (18 boys, 18 girls), who remained untreated, served as controls. The changes in refractive status of 114 eyes in 57 children were collected and compared for patients treated with 0.05% atropine eyedrop and those without medical control. The initial spherical equivalent of refractive status range was between -0.5 and -5.5 D. Mean myopia progression for the group of patients treated with 0.05% atropine eyedrop (n = 21) was -0.28 +/- 0.26 D/year, significantly lower than that of the control group of -0.75 +/- 0.35 D/year (36 patients; P < 0.001). The 0.05% atropine group had a significant lower ratio of uncontrolled myopia, that progressed greater than -0.50 D in 1 year, relative to the controls (16.7% versus 77.8%; P < 0.001).
  
  
  CONCLUSIONS
  The results of this study demonstrate that, with regular instillation, topical 0.05% atropine is an effective agent for controlling myopia progression in a majority of school-aged children for at least a period of 1 year.
authors.affiliation: Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.
authors.forename: Jong-Jer
authors.initials: JJ
authors.lastname: Lee
authors.forename: Po-Chiung
authors.initials: PC
authors.lastname: Fang
authors.forename: I-Hui
authors.initials: IH
authors.lastname: Yang
authors.forename: Chih-Hsin
authors.initials: CH
authors.lastname: Chen
authors.forename: Pei-Wen
authors.initials: PW
authors.lastname: Lin
authors.forename: Sue-Ann
authors.initials: SA
authors.lastname: Lin
authors.forename: Hsi-Kung
authors.initials: HK
authors.lastname: Kuo
authors.forename: Pei-Chang
authors.initials: PC
authors.lastname: Wu
mesh_terms: D001285:Atropine / Q000627:therapeutic use*; D016022:Case-Control Studies; D002648:Child; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009184:Mydriatics / Q000627:therapeutic use*; D009216:Myopia / Q000517:prevention & control*; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D012189:Retrospective Studies; D013624:Taiwan
chemical_list: D009184:Mydriatics; D009883:Ophthalmic Solutions; D001285:Atropine